ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Agios Pharmaceuticals, Inc. ?
1
Poor Management Efficiency with a low ROE of 9.08%
- The company has been able to generate a Return on Equity (avg) of 9.08% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of -23.27% and Operating profit at -12.72% over the last 5 years
3
With a growth in Net Sales of 3.9%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 2 consecutive quarters
- NET PROFIT(HY) Higher at USD -207.15 MM
- NET SALES(Q) Highest at USD 20.75 MM
- OPERATING PROFIT MARGIN(Q) Highest at -523.77 %
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -3.77%, its profits have fallen by -161.3%
5
Rising Promoter Confidence
- Promoters have increased their stake in the company by 2.68% over the previous quarter and currently hold 8.56% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Agios Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Agios Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Agios Pharmaceuticals, Inc.
-3.77%
-0.36
77.21%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-23.27%
EBIT Growth (5y)
-12.72%
EBIT to Interest (avg)
-324.10
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.60
Sales to Capital Employed (avg)
0.03
Tax Ratio
6.23%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
9.08%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.83
EV to EBIT
-2.87
EV to EBITDA
-2.90
EV to Capital Employed
3.79
EV to Sales
25.05
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-132.22%
ROE (Latest)
-34.60%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend18What is working for the Company
NET PROFIT(HY)
Higher at USD -207.15 MM
NET SALES(Q)
Highest at USD 20.75 MM
OPERATING PROFIT MARGIN(Q)
Highest at -523.77 %
RAW MATERIAL COST(Y)
Fallen by -19.67% (YoY
-7What is not working for the Company
NET PROFIT(9M)
At USD -310.58 MM has Grown at -140.75%
INVENTORY TURNOVER RATIO(HY)
Lowest at 0.37 times
DEBTORS TURNOVER RATIO(HY)
Lowest at 6.78 times
Here's what is working for Agios Pharmaceuticals, Inc.
Net Sales
Highest at USD 20.75 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Sales
At USD 20.75 MM has Grown at 53.59%
over average net sales of the previous four periods of USD 13.51 MMMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Profit Margin
Highest at -523.77 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Net Profit
Higher at USD -207.15 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Raw Material Cost
Fallen by -19.67% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Agios Pharmaceuticals, Inc.
Inventory Turnover Ratio
Lowest at 0.37 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debtors Turnover Ratio
Lowest at 6.78 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
